Genzyme in Europe: The Moment of Truth
Executive Summary
Genzyme has long had a presence in Europe, but it now faces its most public challenges. With Fabrazyme having to share its orphan drug exclusivity, and sales of key growth-driver Renagel below expectations, the US firm is finding that although experience helps, it doesn't guarantee a leading market share.